Advaxis to Present at the 2012 Southern California Investment Forum & the OneMedForum NY 2012 Confer

Advaxis, Inc., (ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Thomas Moore, Chairman & CEO of Advaxis, will present at the 2012 Southern California Investment Forum that will take place July 10th&11th,

Online PR News – 12-July-2012 – Las Vegas, NV – Advaxis, Inc., (ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Thomas Moore, Chairman & CEO of Advaxis, will present at the 2012 Southern California Investment Forum that will take place July 10th&11th, 2012 in both San Francisco, California and Las Vegas, Nevada. Thomas Moore, Chairman & CEO of Advaxis, will also present at the OneMedForum NY 2012 Conference on July 12th at 10.40am EST at the Metropolitan Club. The presentation will be webcast at OneMedPlace. About the Southern California Investment Forum The Southern California Investment Forum (SCIF), is an expansion of the ongoing road-show and conference activities of WallStreet Research™, a thirty year old independent research firm, which has been running conferences, road shows and investor gatherings nationally for over twenty years. For more information please visit: www.SouthernCaliforniaInvestmentForum.com. About the OneMedForum NY 2012 Conference OneMedForum New York is the definitive conference in North America for fast-growing and emerging healthcare and life science companies. Now in its third year, the bi-annual forum invites companies with disruptive technology to connect with high-net worth strategic and financial investors in the space. The forum will introduce emerging companies to a privileged network of investors through unique meeting platforms, workshops and more. Additional information can be found at: http://www.onemedplace.com/forum/. About Advaxis, Inc. Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. In April 2012, Advaxis’ lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the World Vaccine Congress website. Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn Forward-Looking Statements This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements. Contact: Advaxis, Inc. Diana Moore, 609-452-9814 Director, Investor Relations & Business Development dmoore@advaxis.com or Media: Russo Partners Matt Middleman, M.D. David Schull T: 212-845-4272 T: 212-845-4271 matt.middleman@russopartnersllc.com david.schull@russopartnersllc.com

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information
Jhonny
Bestotc
5440 W. Sahara Ave., Suite 205
Las Vegas NV, 89146

702 448 1543